Latest Commercialisation News

Yojee's December quarter report reveals solid transaction growth, successful Global Air deployment in Singapore, and promising progress on its MOSAIC platform, supported by a strong cash position and no debt.

Thrive Tribe Technologies has strengthened its cash position through multiple capital raises and appointed Jade Spooner as its new CEO, while its Slik investment achieved profitability in Q4 2024.

Horseshoe Metals has broadened its Horseshoe Lights project area and entered a strategic agreement with Melody Gold to process gold surface materials, advancing its copper-gold development plans in Western Australia.

Spenda Limited has reported a record-breaking quarter with cash receipts soaring 160% year-on-year and payment volumes more than doubling, signaling strong momentum as it advances toward profitability.

Skin Elements Limited reports steady progress in commercialising its plant-based SE Formula biotechnology, highlighted by ongoing product trials, a successful R&D rebate, and a $513k non-renounceable entitlement issue.

Environmental Clean Technologies Limited has formed a joint venture and launched field trials for its innovative COLDry lignite-nitrogen fertiliser, marking a pivotal step toward commercialisation and revenue generation.

Advanced Health Intelligence Ltd (AHI) has secured USD 4 million in convertible debt funding and launched two new commercial partnerships in Canada and the UK, marking significant progress despite its ongoing ASX trading suspension.

High Peak Royalties reported robust cash receipts and successfully repaid its Macquarie Bank facility in the December 2024 quarter, while advancing its geothermal exploration strategy in South Australia.

Nanoveu Limited reports strong momentum in its EyeFly3D technology with a significant purchase order and launches an AI-powered app, while advancing its strategic acquisition of semiconductor innovator EMASS.

Cadoux Limited reports significant progress in its high purity alumina and Minhub rare earths projects, alongside robust environmental, social, and governance initiatives.

Recce Pharmaceuticals has gained key regulatory and ethics approvals for its Phase 3 clinical trial in Indonesia and completed patient dosing for its Phase II trial, while securing a substantial A$6.75 million R&D tax rebate to bolster its financial position.

Cardiex Limited reported a $2.94 million cash outflow for Q2 FY2025 but bolstered its balance sheet with a $3.25 million placement. The company has begun delivering its CONNEQT Pulse units, signaling a new revenue stream and ongoing R&D investment.